3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
8
Terminated
5
Active not recruiting
5
Recruiting
3
Unknown
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Conditions
Carcinoma, Non-Small-Cell Lung
93
Lung Neoplasms
35
Meningeal Carcinomatosis
11
Neoplasms
10
Neoplasm Metastasis
8
Colorectal Neoplasms
6
Adenocarcinoma of Lung
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Mesothelioma, Malignant
4
Non-squamous Non-small Cell Lung Cancer
3
NSCLC
3
Mesothelioma
3
Carcinoma
3
Advanced Solid Tumors
3
Pancreatic Neoplasms
2
Non Squamous Non Small Cell Lung Cancer
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Endometrial Neoplasms
2
Carcinoma, Bronchogenic
2
Bronchial Neoplasms
2
Breast Neoplasms
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sexual Dysfunction, Physiological
1
Interventions
Cisplatin
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
10
Specimen Handling
9
Paclitaxel
6
Platinum
5
Cyclophosphamide
5
1,2-diaminocyclohexaneplatinum II citrate
5
fludarabine
4
durvalumab
4
cemiplimab
4
Radiotherapy, Intensity-Modulated
4
Radiotherapy
3
Pemetrexed
3
Oxaliplatin
3
Nivolumab
3
Fluorouracil
3
Cetuximab
3
Carboplatin
3
Biopsy
3
poly ICLC
2
fludarabine phosphate
2
cabozantinib
2
atezolizumab
2
Radiation
2
Ipilimumab
2
Interviews as Topic
2
Heavy Ion Radiotherapy
2
Gemcitabine
2
Drug Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma
×
Pemetrexed
×
Clear all
NCT06312137
2026-05-22
TroFuse-019
Merck Sharp & Dohme LLC
Phase 3
Recruiting
780 enrolled
NCT06417814
2026-05-14
TROPION-Lung15
AstraZeneca
Phase 3
Recruiting
744 enrolled
NCT06463665
2025-09-26
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled